Dentsply Sirona Inc Stock Price, News & Analysis

Dentsply Sirona (XRAY) has announced its upcoming investor conference call and live webcast scheduled for Thursday, February 27, 2025, at 8:30 am ET. The event will focus on reviewing the company's fourth quarter and full year 2024 financial results.

Investors and interested parties can access a presentation related to the call through the Investors section of Dentsply Sirona's website. The company has provided multiple ways to participate in the event, including a live webcast available on their investor relations website and a registration link for those planning to join the call directly.

Following the conference call, a webcast replay will be made available on the company's Investors section for those unable to attend the live event.

Dentsply Sirona (Nasdaq: XRAY) announced the repositioning of its Byte business model, emphasizing expanded in-person dentist oversight for treatments. The company aims to leverage Byte's direct-to-consumer (DTC) demand generation capabilities, enhance digital customer journey management, and improve customer service and marketing across its aligner portfolio. Dentsply Sirona will not reinstate at-home Byte Aligner Systems and Impression Kits but will continue to support existing non-contraindicated patients. The company will work with regulatory authorities to obtain necessary clearances before any market launch. CEO Simon Campion highlighted the company's commitment to quality, compliance, and broad access to care. Dentsply Sirona will present this strategy at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025. Presentation materials and a webcast replay will be available on the company's investor website.

Dentsply Sirona (XRAY) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's management team is scheduled to deliver their presentation on Wednesday, January 15, 2025, at 7:30 am PT (10:30 am ET).

Interested parties, including investors, will have access to both a live audio webcast and a webcast replay of the presentation through the Investors section of Dentsply Sirona's website at investor.dentsplysirona.com.

Dentsply Sirona (Nasdaq: XRAY) has announced a quarterly cash dividend declaration by its Board of Directors. The company will pay $0.16 per share of common stock, which indicates an annual rate of $0.64 per share. Shareholders who are holders of record as of December 27, 2024, will receive the dividend payment on January 10, 2025.

Dentsply Sirona (Nasdaq: XRAY) has announced its participation in the 7th Annual Evercore ISI HealthCONx Conference. The company's management will engage in a fireside chat discussion on December 5, 2024, at 8:20 am ET. Interested parties can access both the live audio webcast and replay through the Investors section of Dentsply Sirona's website at investor.dentsplysirona.com.

Dentsply Sirona (Nasdaq: XRAY) has appointed Herman V. Cueto as Interim Chief Financial Officer, effective immediately. Cueto brings over 20 years of experience in healthcare finance leadership. He will oversee the finance organization while the company conducts its search for a permanent CFO. CEO Simon Campion expressed confidence in Cueto's financial acumen, operational expertise, and understanding of the global healthcare sector to help execute strategic priorities during this transition period.

Dentsply Sirona (XRAY) reported Q3 2024 results with net sales of $951 million, up 0.5% year-over-year, with organic sales growth of 1.3%. The company posted a GAAP net loss of ($494) million, or ($2.46) per share, including a non-cash goodwill impairment charge of ($495) million. Adjusted EPS was $0.50, slightly up from $0.49 in Q3 2023. Due to market pressures in U.S. equipment and challenges with Byte, the company revised its FY24 outlook, now expecting organic sales decline of (3.5%) to (2.5%) and adjusted EPS of $1.82 to $1.86.

Dentsply Sirona (Nasdaq: XRAY) has announced a conference call and live webcast scheduled for October 25, 2024, at 9:00 am ET to discuss their Byte Aligner business. Interested participants can register for the call through the provided registration link. A replay of the webcast will be made available in the Investors section of the company's website after the call concludes.

Dentsply Sirona (XRAY) has voluntarily suspended sales and marketing of its Byte Aligners and Impression Kits while reviewing regulatory requirements in consultation with the FDA. The company reports preliminary Q3 2024 net sales of approximately $951 million with adjusted EPS expected between $0.49-$0.51. The company expects to record non-cash goodwill impairment charges of $450-$550 million for its Orthodontic Aligner Solutions and Implants & Prosthetic Solutions units, driven by state regulatory impacts on Byte business and weakened demand with competitive pricing pressures.